Previous 10 | Next 10 |
Gainers: Scopus BioPharma (SCPS) +97%.MMA Capital (MMAC) +58%.Aptorum (APM) +37%.Creative Realities (CREX) +33%.Obalon Therapeutics (OBLN) +30%.Regional Health Properties (RHE) +24%.Taiwan Liposome (TLC) +21%.Virgin Galactic (SPCE) +19%.Verastem (VSTM) +18%.Veritiv (VRTV) +17%.Loser...
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) announced results from its 24-week phase 2b study that aveluates aldafermin in 171 patients with biopsy confirmed non-alcoholic steatohepatitis with state 2 or 3 liver fibrosis. The trial was randomized, double blind, plac...
NEW YORK, NY / ACCESSWIRE / May 24, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty claims against NGM Biopharmaceuticals, Inc. (NASDAQ:NGM). On May 24, 2021, NGM Biop...
NGM Biopharmaceuticals (NGM) -46% after NGM Bio abandons NASH candidate following phase 2 failure.Meten EdtechX Education (METX) -27% after prices $40M underwritten public offering.Moxian (MOXC) -9%.Navios Maritime Partners (NMM) -8%.GSX Techedu (GOTU) -8%. For further d...
NGM Bio (NGM) will no longer pursue development of aldafermin for non-alcoholic steatohepatitis ("NASH") after phase 2b results failed to meet its primary endpoint.Evaluating a dose response, the candidate did not demonstrate improvement in liver fibrosis without NASH worsening at week 24.Oth...
Study did not meet primary endpoint of fibrosis improvement by > 1 stage with no worsening of NASH versus placebo Statistical significance achieved versus placebo on certain secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of ...
SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 m...
NGM Biopharmaceuticals (NGM): Q1 GAAP EPS of -$0.36 beats by $0.05.Revenue of $21.58M (-11.4% Y/Y) misses by $0.91M.Press Release For further details see: NGM Biopharmaceuticals EPS beats by $0.05, misses on revenue
Expect to report topline data from Phase 2b ALPINE 2/3 clinical trial of aldafermin in patients with NASH with F2 and F3 liver fibrosis in the second quarter Continued enrollment in Phase 2 CATALINA study of NGM621 in patients with geographic atrophy and expect to complete enrollmen...
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today the nomination of Roger M. Perlmutter, M.D., Ph.D., ...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...